Evaluation of the effect of furosemide inhalation versus placebo in patients with acute cardiogenic pulmonary edema

The study is aimed to evaluate the effect of 40 milligram of inhaled Furosemide versus placebo in patients with early diagnosis of cardiogenic pulmonary edema. The study is a randomized controlled clinical trial that will be conducted in Hazrat-e Rasool-e-Akhram and Firoozghar Hospitals affiliated by Iran University of Medical Sciences during the first half of 2018. This study will be double-blind in which patients and doctors assessing the clinical status of patients will not be aware of the intervention. All patients with primary diagnosis of acute pulmonary involvement will be included in the study, and the exclusion criteria are history of susceptibility to sulfa-containing drugs, inability of the patient to cooperate; unstable hemodynamics; requiring mechanical ventilation; decreased consciousness. 120 patients will be assigned to the treatment group (60) and control (60) using the blocked randomized method. In the treatment group, 40 milligram of Furosemide is inhaled in addition to routine treatment. In control group, Normal Saline will be prescribed as a placebo in addition to routine treatment. The intervention time is within the first 10 minutes of treatment. Patients in both groups will be evaluated at baseline and 10 minutes after intervention in terms of oxygen saturation, respiration rate, heart rate, arterial blood gases, dyspnea based on visual analog scale (VAS), Crackles and Wheezing and decreased lung sounds.

Vice chancellor for research, Iran University of Medical Sciences